Cargando…

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma

OBJECTIVE: Our study aimed to investigate the potential clinical utility of a poly(ADP‐ribose) polymerase (PARP) inhibitor, veliparib (ABT‐888), as a radiosensitizer in the medication of endometrial carcinoma (EC). METHODS: Human Ishikawa endometrial adenocarcinoma cells were treated with veliparib,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Xing, Weizhen, Lin, Yanling, Uskenbayeva, Nuray, Yan, Hongchao, Xu, Yang, Fang, Lisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102625/ https://www.ncbi.nlm.nih.gov/pubmed/35421273 http://dx.doi.org/10.1002/jcla.24435

Ejemplares similares

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
por: Tuli, R., et al.
Publicado: (2019)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
por: Stodtmann, Sven, et al.
Publicado: (2021)

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2018)

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2022)

Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
por: Koppensteiner, Romana, et al.
Publicado: (2014)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Barcellini, Amelia, et al.
Publicado: (2021)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor
por: Zhang, Peng, et al.
Publicado: (2019)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment
por: Li, Yuan, et al.
Publicado: (2019)

In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus
por: Li, Y. F., et al.
Publicado: (2020)

Sensitizing thermochemotherapy with a PARP1-inhibitor
por: Oei, Arlene L, et al.
Publicado: (2016)

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor: Erratum
por: Zhang, Peng, et al.
Publicado: (2022)

Determinants of Sensitivity to Radiotherapy in Endometrial Cancer
por: Sorolla, Maria Alba, et al.
Publicado: (2020)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
por: Philip, Charles-André, et al.
Publicado: (2017)

The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
por: Cai, Lisha, et al.
Publicado: (2022)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer
por: Sharma, Sachin, et al.
Publicado: (2023)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
por: Mann, Minakshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hj2c8p51lovhg8dja5lvokum5r